Steven's Johnson Syndrome and toxic epidermal necrolysis prevalence and causative factors at Khartoum dermatology teaching hospital (2010-2020)

Randa Hamid Musa Marahid; Minas Mohamed Najib; Zainab Mohamed Rahman

doi:10.18203/issn.2455-4529.IntJResDermatol20261560

Authors

Randa Hamid Musa Marahid Department of Dermatology, Tadawi Medical Centre, Doha, Qatar
Minas Mohamed Najib Department of Dermatology, Hassan AL-Abdaalah Medical Centre, Doha, Qatar
Zainab Mohamed Rahman Department of Dermatology, Medical Services, Doha, Qatar

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20261560

Keywords:

Antibiotics, NSAID, Stevens Johnson syndrome, Toxic epidermal necrolysis

Abstract

Background: Cutaneous drug reactions mainly Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) and their overlap are rare but potentially fatal reactions endangers patient’s life, they are characterized by epidermal necrosis which causes erosions of the mucous membranes, extensive detachment of the epidermis. Drugs are the major causes of SJS\TEN. The types of the drugs depend on the prevalent diseases in the country and the protocols of management in that country. The aim of this study was to determine prevalence, causative factors and their correlation with SJS / TEN and their overlap, among patients admitted to Khartoum Dermatology and Venereology Hospital from January 2010 to September 2020.

Methods: This retrospective cross-sectional study investigated 295patients with severe cutaneous reactions. Information collected included participants’ socio-demographic variables, clinical characteristics of the disease and the possible triggers. Data were analyzed using SPSS version 23.0.

Results: The main age distribution was between 20-40 years in (42.7%), 48.8% of the cases had SJS, 44.4% had TEN and only 6.8% had SJS\TEN overlap. Seventy-two percent of the patients had no past history of similar condition. Sixty-six percent of the patients developed cutaneous symptoms from first till the seventh day after drugs intake. Drugs were determined to be the causative agent in 90.5% followed by other risk factors 7.5% mainly; chicken pox and dukhan dermatitis, (2%) of cases were idiopathic. The most common drugs implicated were antibiotics (75.6%), followed by NSAIDs (37.6 %). Patients who passed away during the study period were 24/295 cases (8.1%), 16 patients due to TEN, 6 patients with SJS and 2 patients with SJS/TEN overlap.

Conclusions: SJS was the most common subtype of SJS/TEN in Khartoum Dermatology Hospital but most deaths occur among TEN patients. Women and persons aged 21–40 years were the most affected groups and was attributed to use of drugs, especially antibiotics (Ciprofloxacin), followed by NSAIDs (Diclofenac sodium).

References

Svensson CK, Cowen EW, Gaspari AA. Cutaneous Drug Reactions. Pharmacol Rev. 2001;53(3):357-79.

Patel TK, Barvaliya MJ, Sharma D, Tripathi C. A systematic review of the druginduced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian J Dermatol Venereol Leprol. 2013;79(3):389-98.

Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-7

Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7(2):142–60.

Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology and immunopathogenesis. J Am Acad Dermatol. 2013;69(2):171–13.

Chan HL, Stern RS, Arndt KA. The incidence of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1):43–7.

Naveen KN, Pai VV, Rai V, Athanikar SB. Retrospective analysis of Steven Johnson syndrome and toxic epidermal necrolysis over a period of 5 years from northern Karnataka, India. Indian J Pharmacol. 2013;45(1):80–2.

Rzany B, Mockenhaupt M, Stocker U, Hamouda O, Schopf E. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol. 1993;129(8):1059.

Saha K. Toxic epidermal necrolysis: Current concepts in pathogenesis and treatment. Indian Dermatol Venereol Leprol. 2000;66(1):10-7.

Mockenhaupt M, Viboud C, Dunant A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35–44.

Sassolas B, Haddad C, Mockenhaupt M. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. ClinPharmacolTher. 2010;88(1):60–8.

Breathnach SM. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Blackwell Sci. 2004;1:53-47.

Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5(1):39.

Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87:144-8.

Barvaliya M, Sanmukhani J, Patel T, Paliwal N, Shah H, Tripathi C. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and SJS-TEN overlap: a multicentric retrospective study. J Postgrad Med. 2011;57(2):115–9.

Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death. Arch Dermatol. 2000;136(3):323–7.

Mokenhaupt M, Schopf E. Epidemiology of drug-induced severe skin reactions. SeminCutan Med Surg. 1996;15(4):236-43.

Abdalla S, Edries A, Ali H. Morbidity and mortality of toxic epidermal necrolysis and stevenjonson syndrome TEN/SJS among Sudanese patients, European J Pharmaceutical and Med Res. 2017;4(03):528-32.

Salman H, Kamal S. Retrospective study in patients presented with Toxic Epidermal Necolysis and Stevens Johnson Syndrome in Khartoum Dermatology Hospital, (S.M.S.B), Thesis, 2010.

Irungu K, Nyamu D, Opanga S. Characterization of Stevens–Johnson Syndrome and toxic epidermal necrolysis among patients admitted to Kenyatta national hospital: a retrospective cross-sectional study. drugs. Real World Outcomes. 2017;4:79–85.

Yang S, Hu S,Zhang S. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China. J Immunol Res. 2018;10:4320.

Robert G, Fuxench ZC. Stevens-Johnson syndrome/toxic epidermalnecrolysis: a multicenter retrospective study of 377 adult patients from the United States. J Inv Dermatol. 2018;4:875.

Taylor WRJ, White NJ. Antimalarial drug toxicity: a review. Drug safety. 2004;27(1):25.